Inference-Time Steering Across Scaffolds and Epitopes for Sample-Efficient De Novo Nanobody Design
Organizations: Alloy Therapeutics Allschwil, Switzerland
Abstract
Generative molecular design typically relies on over-generation and post-hoc filtering. Inference-time steering methods like Feynman-Kac (FK) steering improve efficiency by biasing trajectories toward high-reward candidates, yet they optimize within a single fixed configuration. In de novo nanobody design, upfront commitment to conditioning choices like scaffold identity or target epitope creates a bottleneck. Since yield varies across these conditions, steering unpromising setups wastes compute. We recast generative condition selection as an inference-time resource-allocation problem. We propose two dynamic budget allocators: a joint Global Sequential Monte Carlo (SMC) formulation that steers and allocates compute across configurations concurrently, and a decoupled approach adapting Batched Successive Elimination (BaSE). Empirically, these dynamic allocators increase the yield of designable candidates per GPU-hour nearly 5 without sacrificing diversity across distinct therapeutic targets and generative configurations.
Figures & tables
| Steered | |||
| Target (Scaffold) | Vanilla | Fixed | ESS |
| Designable / GPU-h | |||
| PD-L1 (7eow) | 10.6 0.9 | 16.9 0.6 | 14.4 0.5 |
| IL-7R (7xl0) | 9.4 0.3 | 17.8 1.2 | 15.3 1.3 |
| BHRF1 (7eow) | 4.8 0.3 | 7.0 2.8 | 6.3 0.8 |
| Pass Rate (%) | |||
Appendix figures & tables8 assets
Supplementary material from the paper’s appendix.
Appendix
| Epitope | Nominated hotspot residues (PDB numbering) |
|---|---|
| Ep1 [ 18 ] | Phe65, Thr74, Glu77, Asp82, Ser85, Arg93 |
| Ep2 [ 10 ] | Val86, Ile90, Arg93 |
| Ep3 | Glu77, His78, Leu81 |
| Hotspot off | none nominated |
| Scaffold / Source a | FR Identity b | CDR-H3 Len. | Insertions c |
| 8coh | 85.0 % | 19 | 3 / 3 / 7 |
| sonelokimab | 90.0 % | 17 | 3 / 4 / 4 |
| 7eow | 85.0 % | 21 | 3 / 3 / 7 |
| 7xl0 | 87.5 % | 15 | 3 / 3 / 6 |
| 8z8v | 91.2 % | 8 | 3 / 3 / 3 |
| isecarosmab | 88.8 % | 8 | 3 / 2 / 2 |